Your shopping cart is currently empty

5-Fluoromethylornithine dihydrochloride (5-FMOrn dihydrochloride) is a selective inhibitor of L-Ornithine:2-oxoacid aminotransferase (OAT) and a specific inactivator of OAT, which can be used to study metabolic diseases and neurological diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $142 | In Stock | In Stock | |
| 5 mg | $355 | In Stock | In Stock | |
| 10 mg | $528 | - | In Stock | |
| 25 mg | $855 | - | In Stock |
| Description | 5-Fluoromethylornithine dihydrochloride (5-FMOrn dihydrochloride) is a selective inhibitor of L-Ornithine:2-oxoacid aminotransferase (OAT) and a specific inactivator of OAT, which can be used to study metabolic diseases and neurological diseases. |
| In vitro | Incubation for 1 h of L-ornithine carbamoyltransferase, ODC and GABA-T preparations with up to 10 mM 5-Fluoromethylornithine and subsequent determination of the residual enzyme activity demonstrated that none of these enzymes was inactivated. 5-Fluoromethylornithine is a poor substrate of ODC; at 10 mM 5-Fluoromethylornithine, 0.04 nmol of 1-fluoromethylputrescine was formed/h per mg of protein. [1] |
| In vivo | After intraperitoneal administration of 10 mg of 5-Fluoromethylornithine /kg, there is a rapid decrease of OAT activity in all organs, to a basal value. The time-dependence of the effect of 5-Fluoromethylornithine in brain. Minimum activity was usually observed between 2 and 24 h after 5-Fluoromethylornithine administration, thereafter OAT activity recovered gradually. [1] |
| Synonyms | 5-FMOrn dihydrochloride |
| Molecular Weight | 237.1 |
| Formula | C6H15Cl2FN2O2 |
| Cas No. | 124796-41-4 |
| Smiles | O=C(C(CCC(CF)N)N)O.Cl.Cl |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 80 mg/mL (337.41 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.44 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.